MX2018002304A - Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono. - Google Patents
Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono.Info
- Publication number
- MX2018002304A MX2018002304A MX2018002304A MX2018002304A MX2018002304A MX 2018002304 A MX2018002304 A MX 2018002304A MX 2018002304 A MX2018002304 A MX 2018002304A MX 2018002304 A MX2018002304 A MX 2018002304A MX 2018002304 A MX2018002304 A MX 2018002304A
- Authority
- MX
- Mexico
- Prior art keywords
- metabolism
- stimulation
- citrate
- mineral compositions
- hydration
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000004060 metabolic process Effects 0.000 title abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
- 230000036571 hydration Effects 0.000 title 1
- 238000006703 hydration reaction Methods 0.000 title 1
- 229910052500 inorganic mineral Inorganic materials 0.000 title 1
- 239000011707 mineral Substances 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 150000001860 citric acid derivatives Chemical class 0.000 abstract 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 abstract 1
- 239000001354 calcium citrate Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 230000006567 cellular energy metabolism Effects 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 229960005336 magnesium citrate Drugs 0.000 abstract 1
- 239000004337 magnesium citrate Substances 0.000 abstract 1
- 235000002538 magnesium citrate Nutrition 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 235000013337 tricalcium citrate Nutrition 0.000 abstract 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 abstract 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 abstract 1
- 229940068475 zinc citrate Drugs 0.000 abstract 1
- 235000006076 zinc citrate Nutrition 0.000 abstract 1
- 239000011746 zinc citrate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
En esta memoria se describen nuevos aplicaciones de mezclas a base de tres o más sales citrato, que comprenden citrato de magnesio, comprendiendo la mezcla a base de tres o más sales citrato adicionalmente citrato de calcio y/o citrato de zinc, en particular para estimular o potenciar el metabolismo de los hidratos de carbono, preferiblemente el metabolismo de la glucosa, en particular para estimular o potenciar el metabolismo energético celular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15182351.5A EP3135273B1 (de) | 2015-08-25 | 2015-08-25 | Mineralstoffzusammensetzungen zur anregung des kohlenhydratstoffwechsels |
| PCT/EP2016/069522 WO2017032665A1 (de) | 2015-08-25 | 2016-08-17 | Mineralstoffzusammensetzungen zur anregung des kohlenhydratstoffwechsels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018002304A true MX2018002304A (es) | 2018-08-01 |
| MX389506B MX389506B (es) | 2025-03-20 |
Family
ID=54011600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002304A MX389506B (es) | 2015-08-25 | 2016-08-17 | Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3135273B1 (es) |
| AU (1) | AU2016311131B2 (es) |
| MX (1) | MX389506B (es) |
| RU (1) | RU2018110274A (es) |
| WO (1) | WO2017032665A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102017011958A1 (de) * | 2017-12-22 | 2019-06-27 | Marco Loh | Zubereitung zur Mineralisierung von Trinkwasser |
| WO2019201707A1 (de) * | 2018-04-19 | 2019-10-24 | Prosalix Ag | Stoffgemisch umfassend k-mg-citrat zur verwendung als arzneimittel |
| JP6792848B2 (ja) * | 2018-05-25 | 2020-12-02 | 国立大学法人 琉球大学 | 代謝改善剤 |
| DE102019128196A1 (de) | 2019-10-18 | 2021-04-22 | Prosalix Ag | Präparat zur medizinischen Verwendung für die Behandlung einer Krankheit infolge Schädigung der tubulären Nierenfunktion |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19963034A1 (de) | 1999-12-24 | 2001-06-28 | Roche Diagnostics Gmbh | System zur verbesserten Bestimmung des Glukosespiegels anhand von Messungen in interstitieller Flüssigkeit |
| US20030004215A1 (en) * | 2001-06-15 | 2003-01-02 | Van Laere Katrien Maria Jozefa | Dietetic preparation and method for inhibiting intestinal carbohydrate absorption |
| US20030099626A1 (en) * | 2001-11-20 | 2003-05-29 | Health Education Corporation | Nutrient absorption enhancing compositions and methods |
| DE10160485A1 (de) * | 2001-12-08 | 2003-10-02 | Degussa | Verwendung von Kreatin und/oder einem seiner physiologisch geeigneten Derivate zur Prävention oder Linderung von nicht krankheitsbedingten Beeinträchtigungen und/oder Störungen der Muskelfunktion |
| FR2883132B1 (fr) * | 2005-03-15 | 2009-02-13 | Larena Sa | Composition alimentaire suppletive |
| US10251909B2 (en) * | 2007-02-09 | 2019-04-09 | Board Of Regents, The University Of Texas System | Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension |
| US8142803B2 (en) * | 2007-03-22 | 2012-03-27 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| EP2072046A1 (de) * | 2007-12-21 | 2009-06-24 | K.F. Prof. Dr. Kopp | Verwendung einer hydrocarbonathaltigen Zubereitung zur Prävention oder Behandlung von Herz-Kreislauf-Erkrankungen, Diabetes, Osteoporose und chronischem Nierenversagen |
| IT1406068B1 (it) * | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
-
2015
- 2015-08-25 EP EP15182351.5A patent/EP3135273B1/de active Active
-
2016
- 2016-08-17 AU AU2016311131A patent/AU2016311131B2/en active Active
- 2016-08-17 MX MX2018002304A patent/MX389506B/es unknown
- 2016-08-17 RU RU2018110274A patent/RU2018110274A/ru unknown
- 2016-08-17 WO PCT/EP2016/069522 patent/WO2017032665A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017032665A1 (de) | 2017-03-02 |
| RU2018110274A (ru) | 2019-09-26 |
| AU2016311131A1 (en) | 2018-03-15 |
| MX389506B (es) | 2025-03-20 |
| EP3135273B1 (de) | 2020-07-15 |
| EP3135273A1 (de) | 2017-03-01 |
| RU2018110274A3 (es) | 2019-10-29 |
| AU2016311131B2 (en) | 2021-06-24 |
| NZ740091A (en) | 2021-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900019A (es) | Inhibidores de procesos metabólicos celulares | |
| CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| MX2019007276A (es) | Composiciones y métodos para mejora o aumento de la producción de ifn tipo i. | |
| CR20190063A (es) | 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2 | |
| GT201400147A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
| ECSP15026557A (es) | Compuestos y sus métodos de empleo | |
| CL2018001108A1 (es) | Composiciones y métodos para transducción de tumores | |
| AR097481A1 (es) | Cocristales energéticos para el tratamiento de una formación subterránea | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| MX2016012176A (es) | Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva. | |
| SV2017005373A (es) | Inhibidores de la proteína quinasa c y métodos de su uso | |
| AR102148A1 (es) | Composiciones y combinaciones para uso como suplementos alimenticios para animales | |
| MX2015011466A (es) | Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora. | |
| BR112017017043A2 (pt) | composições e métodos para aprimorar aparência de pele | |
| MX2019012938A (es) | Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores. | |
| MX2018002304A (es) | Composiciones minerales para la estimulacion del metabolismo de los hidratos de carbono. | |
| CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| UY36373A (es) | Compuestos para usarse en el tratamiento antihelmíntico | |
| MX2017006019A (es) | Apilimod para uso en el tratamiento de melanoma. | |
| CL2015003584A1 (es) | Compuestos nuevos para el tratamiento del cáncer. | |
| AR113514A1 (es) | Composiciones y métodos para mejorar la utilización del fósforo y el calcio en la dieta de los animales | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| CL2020002268A1 (es) | Métodos para mejorar el rendimiento en rumiantes |